Elicio Therapeutics To Present Phase 1 Data On Cancer Vaccine Candidate, ELI-002, In Patients With High Relapse Risk Pancreatic And Colorectal Cancers At The AACR Special Conference On Pancreatic Cancer
Portfolio Pulse from Happy Mohamed
Elicio Therapeutics, Inc. (NASDAQ:ELTX) will present additional data from the Phase 1 study of its lead asset, ELI-002, a therapeutic cancer vaccine candidate, at the AACR Special Conference on Pancreatic Cancer. The data is in addition to the interim data Elicio presented at the ASCO Annual Meeting earlier this year. ELI-002 is designed to treat cancers driven by G12D and G12R mutations in KRAS and is currently being studied in a Phase 1 trial in patients with high relapse risk mKRAS-driven solid tumors.
September 05, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics is set to present additional data from the Phase 1 study of its lead asset, ELI-002, a therapeutic cancer vaccine candidate. This could potentially impact the company's stock positively if the data is promising.
The presentation of additional data from the Phase 1 study of ELI-002 could potentially impact the company's stock positively if the data is promising. Investors and the market often react positively to promising clinical trial data, especially for treatments for serious diseases like cancer.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100